Cellectar Biosciences (CLRB) AI Stock Analysis

• Market Cap: $17.62M
• Dividend Yield: N/A
• Average Volume (3M): 136.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: N/A
• EPS Growth: 73.37%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.39
• Shares Outstanding: 3,192,040
• 10 Day Avg. Volume: 79,616
• 30 Day Avg. Volume: 136,151
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.07
• 1Y Price Target: $15.20
• Price Target Upside: 175.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 34 Underperform
• Price Target: ―

Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company's valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.

Positive Factors

Clinical Success

High clinical success rates for iapopacine indicate strong therapeutic potential, enhancing the company's prospects for FDA approval and market entry.

Regulatory Progress

Regulatory alignment with the FDA for iopofosine's Phase 3 study provides a clear path to market approval, supporting long-term growth potential.

Financial Strengthening

Significant cash inflows from financing activities bolster the company's financial position, extending its cash runway and supporting ongoing R&D efforts.

Negative Factors

Regulatory Delays

Regulatory delays in NDA submission for iopofosine could postpone market entry, impacting revenue generation and strategic timelines.

Increased SG&A Expenses

Rising SG&A expenses due to pre-commercialization efforts may strain financial resources, affecting profitability and operational efficiency.

NASDAQ Compliance Challenges

Non-compliance with NASDAQ listing requirements poses a risk of delisting, which could limit access to capital markets and investor confidence.

Cellectar Biosciences Business Overview & Revenue Model

Company Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

How the Company Makes Money

Cellectar Biosciences makes money primarily through the development and commercialization of its targeted cancer therapies. The company's revenue model is largely dependent on the successful advancement of its drug candidates through clinical trials and eventual approval by regulatory bodies. Additionally, Cellectar may generate revenue through partnerships, licensing agreements, and collaborations with larger pharmaceutical companies, enabling shared development costs and promotional activities. These partnerships can provide upfront payments, milestone payments, and royalties on sales upon successful commercialization of their therapies.

Cellectar Biosciences Financial Statement Overview

Summary

Cellectar Biosciences is in a challenging financial position with zero revenue generation and continuous operational losses. The company heavily relies on external financing for cash flow needs, and its balance sheet shows vulnerabilities with negative or fluctuating equity. The consistent lack of revenue and profitability raises significant concerns about its financial sustainability.

Income Statement

Cellectar Biosciences has consistently reported zero revenue over the years, indicating a lack of commercialized products. The company operates at a loss, with significant negative net income each year. The EBIT and EBITDA margins are negative, reflecting operational challenges and lack of profitability.

Balance Sheet

The company exhibits a high dependency on equity financing, as seen in fluctuating stockholder's equity and negative equity in 2023. The debt-to-equity ratio is low, indicating limited use of debt, but the overall financial position is weak due to ongoing losses and negative equity in recent years.

Cash Flow

Cellectar Biosciences shows recurring negative free cash flow, indicating insufficient cash generation from operations. The company relies on financing activities to sustain operations, as evidenced by large financing cash inflows. Operating cash flow has been consistently negative, reflecting operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-38.26M	-51.49M	-38.77M	-28.67M	-23.98M	-14.89M
Net Income	-29.07M	-44.58M	-42.77M	-31.79M	-24.12M	-15.09M
Balance Sheet
Total Assets	13.70M	25.47M	12.08M	21.59M	37.20M	58.66M
Cash, Cash Equivalents and Short-Term Investments	11.04M	23.29M	9.56M	19.87M	35.70M	57.17M
Total Debt	453.51K	494.00K	552.98K	603.83K	301.74K	421.64K
Total Liabilities	6.23M	11.18M	25.85M	12.05M	4.16M	3.86M
Stockholders Equity	7.47M	14.29M	-13.78M	9.54M	33.05M	54.79M
Cash Flow
Free Cash Flow	-34.64M	-47.69M	-33.24M	-25.45M	-22.71M	-14.00M
Operating Cash Flow	-34.58M	-47.58M	-32.38M	-25.22M	-22.57M	-13.93M
Investing Cash Flow	-61.29K	-104.19K	-864.04K	-225.97K	-141.36K	-62.35K
Financing Cash Flow	19.81M	61.41M	22.94M	9.61M	1.25M	60.55M

Cellectar Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.52
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLRB, the sentiment is Neutral. The current price of 5.52 is above the 20-day moving average (MA) of 5.19, above the 50-day MA of 4.96, and below the 200-day MA of 7.92, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 55.65 is Neutral, neither overbought nor oversold. The STOCH value of 70.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLRB.

Cellectar Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLGL	51 Neutral	80.76M	-23.68	―	―	264.86%	77.14%
AKTX	44 Neutral	31.64M	―	―	―	―	―
CANF	40 Underperform	14.09M	―	-144.96%	―	―	―
CLRB	34 Underperform	$17.62M	―	-273.88%	―	―	73.37%
GOVX	34 Underperform	16.38M	-0.26	―	―	1943.07%	80.97%
ELEV	33 Underperform	20.73M	-0.44	-74.11%	―	―	47.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cellectar Biosciences Corporate Events

Cellectar Biosciences Enhances CEO and COO Severance Benefits

On March 12, 2025, Cellectar Biosciences’ board approved amendments to the employment agreements of its CEO and COO, enhancing their severance benefits in the event of a change in control. Additionally, on March 11, 2025, the board adopted new by-laws to align with Delaware law, revising stockholder nomination procedures and reducing the quorum requirement for meetings.